The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas.
Breast cancer is the main cause of cancer-related death among women in Western countries. Current research is focused on identifying antiapoptotic proteins which could be a possible target for novel chemotherapeutic drugs. Secretory clusterin (sCLU) is an extracellular chaperone that has been functionally implicated in DNA repair, cell-cycle regulation, apoptotic cell death and tumorigenesis. The implication of sCLU in carcinogenesis and the progression of breast carcinomas make it an interesting gene, worthy of investigation. It has been reported to present powerful antiapoptotic activity and to perform a prosurvival function with most therapeutic treatments for breast cancer. This review summarizes our current understanding of the role of CLU in tumorigenesis, progression, and response to treatment in breast carcinomas.
Redondo
Maximino
M
Department of Biochemistry, Hospital Costa del Sol, CIBER Epidemiología y Salud Pública, Universidad de Málaga, Marbella, Spain.
Tellez
Teresa
T
Roldan
María Jose
MJ
D017209:Apoptosis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D051152:Clusterin / Q000032:analysis / Q000502:physiology*; D003907:Dexamethasone / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011379:Prognosis; D013873:Thionucleotides / Q000627:therapeutic use
C495242:CLU protein, human; D051152:Clusterin; D020847:Estrogen Receptor Modulators; C503781:OGX-011; D013873:Thionucleotides; D003907:Dexamethasone